Partner Headlines - EXEL

  1. Mid-Day Market Update: ON Semiconductor Surges On $1 Billion ...

    Benzinga
  2. Mid-Morning Market Update: Markets Open Lower; Weatherford To ...

    Benzinga
  3. Morning Market Losers

    Benzinga
  4. Events for the Week of Nov. 17-21, 2014

    Benzinga
  5. Morning Market Movers

    Benzinga
  6. 5-year lows: National Presto Industries, Ennis Inc, Landauer ...

    GuruFocus
  7. Stocks Hitting 52-Week Lows

    Benzinga
  8. Equities, Commodities & Bonds Finish Lower On First Trading Day ...

    Benzinga
  9. Midday Losers From Tuesday, September 2

    Benzinga
  10. Exelixis Shares Slide On Trial Results; Norwegian Cruise Line ...

    Benzinga
  11. Markets Mixed; Conn's Profit Misses Estimates

    Benzinga
  12. Stocks Hitting 52-Week Lows

    Benzinga
  13. Morning Market Losers

    Benzinga
  14. Benzinga's Top Downgrades

    Benzinga
  15. Stifel Nicolaus Downgrades Exelixis To Hold

    Benzinga
  16. Stocks To Watch For September 2, 2014

    Benzinga
  17. Exelixis Announces Results From COMET-1 Phase 3 Pivotal Trial ...

    Benzinga
  18. Mid-Afternoon Market Update: Harmonic Drops On Weak Forecast; ...

    Benzinga
  19. Harmonic Drops On Weak Forecast; URS Shares Surge

    Benzinga
  20. Mid-Morning Market Update: Markets Open Higher; Citigroup Profit ...

    Benzinga
  21. Morning Market Movers

    Benzinga
  22. Exelixis Shares Move 12% On Phase 3 Data

    Benzinga
  23. Benzinga's Top #PreMarket Gainers

    Benzinga
  24. Conferences/Events Scheduled for Week of Jun. 9th to Jun. 13th

    Benzinga
  25. Benzinga's Top #PreMarket Gainers

    Benzinga
  26. Five-Year Lows: Rentech Nitrogen Partners LP, SandRidge Permian ...

    GuruFocus
  27. Market Wrap For March 26: Markets Close Near Session Lows In ...

    Benzinga
  28. Mid-Afternoon Market Update: Markets Turn Red as Dish Network ...

    Benzinga
  29. Mid-Day Market Update: Five Below Jumps On Upbeat Results; Exelixis ...

    Benzinga
  30. Mid-Morning Market Update: Markets Open Higher; Francesca's Issues ...

    Benzinga
  31. Stocks Hitting 52-Week Lows

    Benzinga
  32. Morning Market Losers

    Benzinga
  33. Benzinga's Top #PreMarket Losers

    Benzinga
  34. Morning Market Movers

    Benzinga
  35. US Stock Futures Rise Ahead Of Housing Data

    Benzinga
  36. Exelixis Prices 10M Share Offering at $8 per Share

    Benzinga
  37. Oversold ETFs Looking Attractive (IHE, CSD, PSCE)

    Benzinga
  38. Exelixis Announces Promising Phase 1b Data for Cobimetinib in ...

    Benzinga
  39. US Stock Futures Rise Ahead Of Jobless Claims, GDP Data

    Benzinga
  40. Exelixis Announces Full Patient Enrollment for COMET-1 Phase ...

    Benzinga
  41. US Stock Futures Up After Upbeat China Data

    Benzinga
  42. Exelixis Initiates Phase 3 Clinical Trial of Cabozantinib

    Benzinga
  43. Exelixis Receives EMA Acceptance of Marketing Authorization App ...

    Benzinga
  44. Exelixis Inc. Reports Operating Results (10-Q)

    GuruFocus
  45. Exel Presents Interim Data for Cabozantinib 40 mg Dose Cohort ...

    Benzinga
  46. First Solar, Sears Holdings Among Stocks Down on Above-average ...

    FoxBusiness
  47. Exelixis Says FDA Says NDA Has Been Removed from November Agenda

    Benzinga
  48. UPDATE: Piper Jaffray Reduces PT to $4.50 on Exelixis on Equity ...

    Benzinga
  49. Social Media Outlook for Thursday August 9 (EAT, NOV, NWSA, FSYS)

    Benzinga
  50. Exelixis, Universal Display Corporation Among Stocks Up on High ...

    FoxBusiness
  51. FDA's Oncologic Drugs Advisory Committee to Review Exelixis New ...

    Benzinga
  52. Exelixis (EXEL) Loses 8.8% As Company Sells Stock, Debt

    MarketIntelligenceCenter
  53. Health Care Sector Wrap

    FoxBusiness
  54. HCA Holdings, American Capital Mortgage Investment Crp Among ...

    FoxBusiness
  55. Interpublic Group, Exelixis Gapping Down Monday

    FoxBusiness
  56. UPDATE: Exelixis Announces Proposed Convertible Debt Offering ...

    Benzinga
  57. Exelixis Proposed Offering 20M Shares

    Benzinga
  58. Exelixis Inc. Reports Operating Results (10-Q)

    GuruFocus
  59. Social Media Outlook for Monday July 30 (SHAW, BBY, EXEL, VHC)

    Benzinga
  60. Benzinga's Top Pre-Market Gainers

    Benzinga
  61. FDA Grants Priority Review for Cabozantinib in Medullary Thyroid ...

    Benzinga
  62. Exelixis Announces Initiation of Cabozantinib Investigator-Sponsored ...

    Benzinga
  63. Jefferies Reiterates Hold Rating, $6 PT for Exelixis

    Benzinga
  64. Cabozantinib Demonstrates Durable Effects in Bone and Soft Tissue ...

    Benzinga
  65. Cabozantinib Meets Primary Endpoint of Progression Free Survival ...

    Benzinga
  66. Cabozantinib Demonstrates Evidence of Anti-Tumor Effects in Heavily ...

    Benzinga
  67. Exelixis Completes Submission of New Drug Application for Cabozantinib ...

    Benzinga
  68. Exelixis Initiates COMET-1 Pivotal Trial Focused on Overall Survival ...

    Benzinga
  69. Exelixis Expands the Cabozantinib Development Program Through ...

    Benzinga
  70. Exelixis Announces Initiation of Investigator-Sponsored Clinical ...

    Benzinga
  71. 5 Resilient Biotech Stocks to Buy for 2012

    GuruFocus
  72. Top 4 NASDAQ Stocks In The Biotechnology Industry With The Lowest ...

    Benzinga
  73. Exelixis (EXEL) Gains 2.8% After Pricing 11 Million Share Offering ...

    MarketIntelligenceCenter
  74. Exelixis Announces Pricing of $60.5 Million Public Offering at ...

    Benzinga
  75. Exelixis Announces Proposed Public Offering of 10M Shares

    Benzinga
  76. Exelixis Reports Positive Preliminary Phase 2 Cabozantinib Data ...

    Benzinga
  77. Notable Call Options Activity on Exelixis

    Benzinga
  78. Exelixis Trading Higher After Licensing Agreement with Merck

    Benzinga
  79. Exelixis Lures Premium Sellers on Positive Drug Data

    SchaeffersResearch
Trading Center